U.S. Markets closed
  • S&P 500

    4,401.51
    -20.79 (-0.47%)
     
  • Dow 30

    35,058.92
    -85.39 (-0.24%)
     
  • Nasdaq

    14,660.58
    -180.14 (-1.21%)
     
  • Russell 2000

    2,186.18
    -30.74 (-1.39%)
     
  • Crude Oil

    71.77
    -0.14 (-0.19%)
     
  • Gold

    1,800.40
    +1.20 (+0.07%)
     
  • Silver

    24.78
    -0.53 (-2.11%)
     
  • EUR/USD

    1.1825
    +0.0017 (+0.1419%)
     
  • 10-Yr Bond

    1.2340
    -0.0420 (-3.29%)
     
  • Vix

    19.16
    +1.58 (+8.99%)
     
  • GBP/USD

    1.3882
    +0.0058 (+0.4178%)
     
  • USD/JPY

    109.7300
    -0.6450 (-0.5844%)
     
  • BTC-USD

    37,963.78
    -744.94 (-1.92%)
     
  • CMC Crypto 200

    895.80
    +19.56 (+2.23%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,970.22
    +136.93 (+0.49%)
     

G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020

·1 min read

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present company updates at two investor conferences in August 2020:

  • BTIG Virtual Biotechnology Conference 2020 on Monday, August 10, 2020 at 11:30 a.m. ET

  • 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:55 a.m. ET

To access live and archived webcasts of the presentations, please visit the Events & Presentations page of the G1 website.

About G1 Therapeutics
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs. Trilaciclib is a first-in-class FDA-designated Breakthrough Therapy designed to improve outcomes for patients being treated with chemotherapy. Rintodestrant is a potential best-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+ breast cancer. Lerociclib is a differentiated oral CDK4/6 inhibitor designed to enable more effective combination treatment strategies.

G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:
Jeff Macdonald
G1 Therapeutics, Inc.
Senior Director, Investor Relations & Corporate Communications
919-907-1944
jmacdonald@g1therapeutics.com